{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:06:15Z","timestamp":1791525975901,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T00:00:00Z","timestamp":1285804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the efficacy and safety of pregabalin alone or in combination with tolterodine extended release (ER) in subjects with idiopathic OAB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 26\u2010week, multicenter, randomized, double\u2010blind, placebo\u2010controlled, three\u2010period crossover study enrolled women aged \u226518 years that were diagnosed with OAB and reported \u22658\u2009micturitions\/24\u2009hr and \u22654 urgency episodes\/week on 5\u2010day bladder diary at baseline. Subjects were randomized to 1 of 10 treatment sequences and received three of five treatments, each for 4 weeks with 4\u2010week washout periods: standard\u2010dose pregabalin\/tolterodine ER (150\u2009mg twice daily [BID]\/4\u2009mg once daily [QD], n\u2009=\u2009102), pregabalin alone (150\u2009mg BID, n\u2009=\u2009105), tolterodine ER alone (4\u2009mg QD, n\u2009=\u2009104), low\u2010dose pregabalin\/tolterodine ER (75\u2009mg BID\/2\u2009mg QD, n\u2009=\u2009105), and placebo (n\u2009=\u2009103). Subjects completed 5\u2010day diaries at the end of treatment and washout periods. The primary endpoint was change from baseline to week 4 in mean voided volume (MVV) per micturition. The primary comparison was standard\u2010dose pregabalin\/tolterodine ER versus tolterodine ER alone; secondary comparisons were pregabalin alone versus tolterodine ER alone and versus placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline\u2010adjusted changes in MVV were significantly greater after treatment with standard\u2010dose pregabalin\/tolterodine ER (39.5\u2009ml) versus tolterodine ER alone (15.5\u2009ml; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), and with pregabalin alone (27.4\u2009ml) versus tolterodine ER alone (<jats:italic>P<\/jats:italic>\u2009=\u20090.005) and placebo (11.9\u2009ml; <jats:italic>P<\/jats:italic>\u2009=\u20090.0006). Treatments were generally well tolerated; discontinuation rates due to adverse events were 4%, 2%, 5%, 0%, and 1% with standard\u2010 and low\u2010dose pregabalin\/tolterodine ER, pregabalin, tolterodine ER, and placebo, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pregabalin, alone or with tolterodine ER may offer an alternative treatment option for idiopathic OAB in women. Neurourol. Urodynam. 30:75\u201382, 2011. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.20928","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T15:00:31Z","timestamp":1285858831000},"page":"75-82","source":"Crossref","is-referenced-by-count":33,"title":["Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder"],"prefix":"10.1002","volume":"30","author":[{"given":"Josef","family":"Marencak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini H.","family":"Cossons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Darekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07601.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20798"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro0054"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07205.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.13.3.431"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000228174.08885.AB"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.5.1243"},{"key":"e_1_2_7_13_2","first-page":"336","article-title":"The use of gabapentine in the treatment of neurogenic detrusor overactivity: Preliminary urodynamic and clinical results","volume":"21","author":"Carbone A","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-55382004000400002"},{"key":"e_1_2_7_15_2","volume-title":"Full prescribing information","author":"Lyrica\u00ae (pregabalin)","year":"2009"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.01.114"},{"key":"e_1_2_7_17_2","first-page":"190","article-title":"Modulators of the \u03b12\u03b4 subunit of neuronal calcium channels inhibit bladder sensory pathways: In vitro patch clamp and in vivo cystometry in rats and cats","volume":"24","author":"Fraser MO","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_7_18_2","first-page":"192","article-title":"Remarkable synergy of neurotropic agents, gabalin and pregabalin, with antimuscarinics: Inhibition of bladder overactivity in the rat and cat","volume":"24","author":"Fraser MO","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-004-0455-3"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802537122"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.007"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016370925601"},{"key":"e_1_2_7_24_2","unstructured":"Overactive Bladder Questionnaires. The OAB\u2010q Short Form (OAB\u2010q SF). 2009 [cited 2009 September 10]; Available from:http:\/\/www.oabq.com\/oab\u2010science.html#OAB\u2010qSF."},{"key":"e_1_2_7_25_2","volume-title":"Full prescribing information","author":"Detrol\u00ae LA (tolterodine tartrate)","year":"2008"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07907.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.07.009"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.08.018"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.05.014"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.20928","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.20928","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.20928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T17:26:04Z","timestamp":1696872364000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.20928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1002\/nau.20928"],"URL":"https:\/\/doi.org\/10.1002\/nau.20928","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,30]]}}}